Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W6WC
|
|||
| Former ID |
DIB016251
|
|||
| Drug Name |
Apolizumab
|
|||
| Synonyms |
Remitogen; Hu 1D10; Hu1D10, PDL; SMART 1D10 MAb, Protein Design Labs; SMART anti-B cell lymphoma
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
| Company |
PDL BioPharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | MHC class II antigen DR (HLA-DR) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma. 2009 Dec;50(12):1958-63. | |||
| REF 2 | A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.